Hernan Gonzalez: This data provides new evidence of the benefit of molecular testing in well selected patients with indeterminate thyroid cytology

Quoting Hernan Gonzalez, Associate Professor of Surgery and Research Director in the Department of Surgical Oncology at Pontifical Catholic University of Chile, on LinkedIn:

”We have just published a new prospective non-interventional study showing real-world clinic utility of ThyroidPrint. Up to 67% of patients undergoing molecular testing for indeterminate thyroid cytology were called benign (Benign Call Rate). With a minimum of 18 months of follow-up, 99% of these patients remained under surveillance. Furthermore, the post-test cancer probability in patients undergoing ThyroidPrint testing was 71% when compared to the 32% of patient that did not undergo testing. This data provides new evidence of the benefit of molecular testing in well selected patients with indeterminate thyroid cytology.”

For the article click here.
Source: Hernan Gonzalez/LinkedIn